GLP-1 Without Needles: Your Non-Injectable Options

Needle anxiety is real, and it's one of the most common reasons people put off starting a GLP-1 program. If the idea of weekly self-injections is a dealbreaker for you, you're not alone, and you're not necessarily out of options.

Non-injectable GLP-1 formats exist. Some are FDA-approved. Others are compounded preparations that pharmacies mix in alternative delivery forms. They come with trade-offs worth understanding before you sign up, but for many people, starting on something needle-free beats not starting at all.

This article covers what formats are available, which providers offer them, and what you'd be giving up compared to injectable semaglutide. If you're undecided between formats and not specifically anxious about needles, the injectable vs. oral GLP-1 decision guide covers the broader comparison in more depth.

Why most GLP-1s are injectable

GLP-1 receptor agonists like semaglutide and tirzepatide are peptide molecules. Peptides break down in the digestive system before they can be absorbed in meaningful amounts, which is why the FDA-approved formulations for most GLP-1s use subcutaneous injection. Injecting the drug bypasses the gut entirely and delivers it into the tissue just below the skin, where it absorbs consistently.

This isn't a design choice; it's a chemistry constraint. Overcoming it requires either a protective delivery mechanism or a different molecular structure altogether.

Non-injectable options that actually exist

Several formats have emerged that let patients avoid injections:

• Oral tablets: either FDA-approved formulations with special absorption technology, or compounded oral tablets made by pharmacy
• Sublingual drops: liquid preparations placed under the tongue
• Sublingual lozenges: dissolvable tablets held under the tongue or in the cheek

Each format solves the delivery problem differently, and each comes with its own evidence base, or lack of one.

Brand-name oral options: Foundayo and Rybelsus

Foundayo (orforglipron)

Foundayo is the newest oral option and, as of April 2026, the only FDA-approved oral GLP-1 medication specifically indicated for weight management in adults (FDA, April 2026). Its active ingredient is orforglipron, a small-molecule GLP-1 receptor agonist (not a peptide), which is precisely why it survives oral digestion. Shed lists Foundayo as one of the brand-name options available through their platform, alongside Wegovy and Zepbound.

Foundayo is a distinct drug from semaglutide. Its long-term clinical profile is still being established compared to the multi-year data available for injectable semaglutide.

Wegovy pill and Rybelsus (oral semaglutide)

The Wegovy oral tablet is now available at several telehealth providers, including Hims, Hers, PlushCare, and WeightWatchers Clinic. It uses an absorption enhancer to get semaglutide through the gut lining and is FDA-approved for weight management — confirm availability and pricing at each provider's signup.

Rybelsus is a different oral semaglutide tablet, but its FDA-approved indication is type 2 diabetes management, not weight loss (DailyMed). Some providers prescribe it off-label for weight management, but patients should understand that this use falls outside its approved indication.

Compounded oral formats: drops, lozenges, and tablets

Compounding pharmacies have developed sublingual and oral formulations of semaglutide that don't require injection. These include:

Sublingual drops: A liquid solution administered under the tongue, where the medication absorbs through the mucous membrane directly into the bloodstream. Among the providers we've reviewed, Shed is the only one currently offering this format. A handful of other compounding-focused programs outside our lineup (such as SkinnyRx) also carry drops if you want to compare further.

Sublingual lozenges: A dissolvable tablet that sits under the tongue or in the cheek. Absorption is similar in mechanism to drops. Shed is again the only provider in our lineup offering lozenges — this format is not widely available across mainstream telehealth programs.

Oral liposomal and compounded tablets: Compounded tablets use lipid-based packaging or other formulation techniques to help semaglutide survive digestion. Shed offers an oral semaglutide liposomal tablet. MEDVi also lists compounded tablet options alongside its injectable program — confirm current availability directly.

One important compliance note: compounded semaglutide in any form — drops, lozenges, or oral tablets — is not an FDA-approved finished product. Compounding pharmacies prepare these formulations from bulk active pharmaceutical ingredients. The individual components may meet pharmaceutical standards, but the finished compounded product has not gone through the FDA's approval process. This is different from taking an FDA-approved medication.

For more on the regulatory distinction between compounded and brand-name semaglutide, see our compounded vs. brand-name semaglutide guide.

What you give up with oral and sublingual formats

Honesty here matters. Non-injectable formats come with real trade-offs.

Bioavailability is lower. Subcutaneous injection delivers semaglutide with high bioavailability (meaning most of the dose reaches systemic circulation) (Wegovy prescribing information, FDA). Oral and sublingual formats absorb at a fraction of that rate. Even the FDA-approved Rybelsus, with its purpose-built absorption enhancer, is designed around this limitation by using higher doses. Compounded sublingual drops and lozenges have not been studied in clinical trials equivalent to those conducted for injectable semaglutide, so their real-world absorption rates are not well characterized.

The evidence base is thinner. The clinical trial data supporting injectable semaglutide for weight loss, including the STEP trials, were conducted with subcutaneous injections. Unlike Wegovy, which was evaluated in large randomized controlled trials, compounded sublingual and oral semaglutide formulations have not been independently studied in equivalent clinical trials. That doesn't mean they don't work, but it means the evidence is less robust.

Consistency matters more. Sublingual drops and lozenges require specific technique: holding the medication under the tongue for a set period, avoiding food or drink around dosing. Small deviations can affect how much drug actually absorbs. Injections are more forgiving.

Cost may be higher, not lower. Compounded injectables are often the cheapest GLP-1 format available. Oral and sublingual compounded formats can cost more per month because of the additional formulation complexity.

Which providers offer needle-free GLP-1s

Most telehealth GLP-1 providers default to injectable semaglutide or tirzepatide. A shorter list offers non-injectable alternatives.

Provider	Non-injectable formats	Starting price	Notes
Shed	Drops, lozenges, oral liposomal tablets, Foundayo, Wegovy pill	$199+/month (varies by format)	Broadest format selection
Hims	Wegovy pill	From $149/mo + membership	Brand-name, Novo Nordisk partner
Hers	Wegovy pill	From $69/mo + membership	Women-focused; oral and injectable
PlushCare	Wegovy pill	$19.99/mo + medication	Insurance-first; oral semaglutide available
WeightWatchers Clinic	Wegovy pill	From $74/mo + medication	Coaching + oral or injectable prescription
MEDVi	Compounded tablet option	$179–$349/mo	Confirm tablet availability at signup
Found	Broad formulary (confirm at signup)	From $129/mo membership	Good for navigating format options
Eden	Injectable only	From $129/mo	Budget-friendly; not for needle-averse patients
Enhance.MD	Injectable only	From $212/mo (annual)	Flat-rate pricing; no oral options

Eden and Enhance.MD are strong options for patients comfortable with injections who want affordable compounded semaglutide. But if avoiding needles is the priority, they're not the right fit.

Shed: the widest format selection

Shed is the provider with the most delivery options under one roof. Their platform lists compounded semaglutide injections, compounded tirzepatide injections, sublingual drops, lozenges, oral semaglutide liposomal tablets, Foundayo, Wegovy, and Zepbound (tryshed.com). That means a patient can start on drops, switch to lozenges if drops don't suit them, or eventually move to an injectable as tolerance builds, all without changing providers.

Pricing at Shed varies by format and dose, with a reported range of $199–$399+/month (per tryshed.com, April 2026). Specific per-format prices are not displayed publicly — you'll need to complete their intake to see exact costs.

Found: broad formulary with guidance

Found carries over 10 weight-loss medications including compounded semaglutide and brand-name GLP-1s (per joinfound.com, April 2026). If you're unsure which format works best for you, Found's clinicians can help you navigate the options. They also do a free insurance check, which matters if you're hoping a brand-name oral option might be covered.

Bottom line

Needle anxiety is a legitimate concern, not an excuse. If it's the reason you've been delaying a GLP-1 program, there are real alternatives worth considering.

The honest trade-off: injectable semaglutide has the strongest evidence base and the most predictable absorption. Oral and sublingual formats offer convenience and accessibility, particularly for patients who genuinely cannot tolerate injections, but they require accepting more uncertainty about how much drug you're actually absorbing.

Two FDA-approved oral options stand out: Foundayo, which is built from the ground up for oral delivery using a non-peptide molecule, and the Wegovy pill, which brings the same active ingredient as injectable Wegovy in tablet form. Both are approved for weight management, both avoid injections entirely, and both carry the regulatory backing that compounded formats lack. If either fits your budget and is available through your provider, they're the most straightforward needle-free choice. Compounded drops and lozenges are a reasonable starting point for patients who need a needle-free entry point and can't access or afford brand-name options, with the understanding that you're working with less clinical data.

For needle-averse patients specifically, Shed stands out for format flexibility — if drops don't suit you, lozenges are an option; if you want to eventually transition to injections, you can do it without switching providers. Found is worth considering if you want clinical guidance on which format fits your situation.

Whatever format you're considering, a licensed provider should evaluate whether it's appropriate for your situation. Dosing, monitoring, and titration differ by format, and a clinician familiar with these nuances will help you get better results.